We next tested whether siRNA-knockdown of TIGAR expression could hypersensitize HPV18+ HeLa cervical carcinoma cells to otherwise sub-inhibitory concentrations of the chemotherapeutic agents: doxorubicin, cisplatin, etoposide, or 4-hydroxycyclophosphamide. Here, TIGAR is linked to cervical carcinoma.